New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

MaxCyte, Inc

Contributing Author

Recent Articles by MaxCyte, Inc

4 hours	MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MXCT GlobeNewswire
Mar-24	MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance MXCT -6.81% MXCT GlobeNewswire
Mar-23	MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer MXCT GlobeNewswire
Feb-24	MaxCyte unveils ExPERT DTx, a 96-well electroporation platform to accelerate discovery MXCT +5.01% GlobeNewswire
Feb-23	MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 MXCT GlobeNewswire
Jan-12	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results MXCT GlobeNewswire
Nov-12	MaxCyte Announces Planned CFO Transition in 2026 MXCT GlobeNewswire
Nov-12	MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Nov-05	MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Oct-08	MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 MXCT +9.68% GlobeNewswire
Oct-06	MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors MXCT GlobeNewswire
Sep-22	MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability MXCT +10.32% MXCT GlobeNewswire
Aug-06	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance MXCT -29.90% MXCT GlobeNewswire
Aug-04	MaxCyte Signs Platform License Agreement with Adicet Bio MXCT GlobeNewswire
Jul-31	MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline MXCT GlobeNewswire
Jul-09	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 MXCT GlobeNewswire
Jun-11	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies MXCT GlobeNewswire
May-07	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT -11.31% MXCT GlobeNewswire
May-07	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT -11.31% MXCT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)